CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.77
3.8%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.06
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Synlogic Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.84
Open* 1.83
1-Year Change* 181.54%
Day's Range* 1.73 - 1.84
52 wk Range 1.61-15.60
Average Volume (10 days) 26.04K
Average Volume (3 months) 1.10M
Market Cap 28.67M
P/E Ratio -100.00K
Shares Outstanding 9.19M
Revenue 708.00K
EPS -12.72
Dividend (Yield %) N/A
Beta 1.22
Next Earnings Date Mar 27, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 4, 2024 1.77 -0.06 -3.28% 1.83 1.84 1.73
Mar 1, 2024 1.84 -0.04 -2.13% 1.88 1.92 1.84
Feb 29, 2024 1.89 0.06 3.28% 1.83 1.92 1.83
Feb 28, 2024 1.85 0.03 1.65% 1.82 1.86 1.82
Feb 27, 2024 1.86 0.02 1.09% 1.84 1.92 1.84
Feb 26, 2024 1.87 0.00 0.00% 1.87 1.90 1.86
Feb 23, 2024 1.87 0.05 2.75% 1.82 1.93 1.82
Feb 22, 2024 1.91 -0.07 -3.54% 1.98 2.12 1.90
Feb 21, 2024 1.94 0.16 8.99% 1.78 1.98 1.72
Feb 20, 2024 1.79 0.07 4.07% 1.72 1.81 1.72
Feb 16, 2024 1.76 -0.03 -1.68% 1.79 1.82 1.74
Feb 15, 2024 1.76 0.07 4.14% 1.69 1.84 1.68
Feb 14, 2024 1.73 0.07 4.22% 1.66 1.74 1.66
Feb 13, 2024 1.68 0.10 6.33% 1.58 1.69 1.53
Feb 12, 2024 1.68 0.05 3.07% 1.63 1.71 1.54
Feb 9, 2024 1.73 0.05 2.98% 1.68 1.81 1.58
Feb 8, 2024 3.43 0.12 3.63% 3.31 3.53 3.30
Feb 7, 2024 3.45 -0.13 -3.63% 3.58 3.58 3.30
Feb 6, 2024 3.48 0.30 9.43% 3.18 3.58 3.18
Feb 5, 2024 3.26 -0.06 -1.81% 3.32 3.33 3.12

Synlogic Events

Time (UTC) Country Event
Wednesday, March 27, 2024

Time (UTC)

12:30

Country

US

Event

Q4 2023 Synlogic Inc Earnings Release
Q4 2023 Synlogic Inc Earnings Release

Forecast

-

Previous

-
Thursday, May 9, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Synlogic Inc Earnings Release
Q1 2024 Synlogic Inc Earnings Release

Forecast

-

Previous

-
Friday, June 14, 2024

Time (UTC)

12:00

Country

US

Event

Synlogic Inc Annual Shareholders Meeting
Synlogic Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 1.18 1.754 0.545 2.224 2.52
Revenue 1.18 1.754 0.545 2.224 2.52
Total Operating Expense 68.599 62.519 61.011 56.633 53.75
Selling/General/Admin. Expenses, Total 16.555 15.392 13.537 14.728 15.716
Research & Development 52.044 47.127 47.474 41.905 38.034
Operating Income -67.419 -60.765 -60.466 -54.409 -51.23
Interest Income (Expense), Net Non-Operating 1.265 0.208 1.296 3.041 2.8
Net Income Before Taxes -66.147 -60.561 -59.173 -51.373 -48.435
Net Income After Taxes -66.147 -60.561 -59.173 -51.373 -48.435
Net Income Before Extra. Items -66.147 -60.561 -59.173 -51.373 -48.435
Net Income -66.147 -60.561 -59.173 -51.373 -48.435
Income Available to Common Excl. Extra. Items -66.147 -60.561 -59.173 -51.373 -48.435
Income Available to Common Incl. Extra. Items -66.147 -60.561 -59.173 -51.373 -48.435
Diluted Net Income -66.147 -60.561 -59.173 -51.373 -48.435
Diluted Weighted Average Shares 4.78194 3.68883 2.38917 2.01904 1.59226
Diluted EPS Excluding Extraordinary Items -13.8327 -16.4174 -24.7672 -25.4443 -30.4191
Diluted Normalized EPS -13.8327 -16.4174 -24.7672 -25.4443 -30.4191
Other, Net 0.007 -0.004 -0.003 -0.005 -0.005
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.035 0.174 0.106 0.678 0.152
Revenue 0.035 0.174 0.106 0.678 0.152
Total Operating Expense 15.689 16.417 17.409 19.012 16.169
Selling/General/Admin. Expenses, Total 3.924 3.967 3.77 4.402 4.112
Research & Development 11.765 12.45 13.639 14.61 12.057
Operating Income -15.654 -16.243 -17.303 -18.334 -16.017
Interest Income (Expense), Net Non-Operating 0.617 0.627 0.61 0.421 0.168
Other, Net -0.002 -0.006 -0.003 0.001 0.007
Net Income Before Taxes -15.039 -15.622 -16.696 -17.912 -15.842
Net Income After Taxes -15.048 -15.622 -16.696 -17.912 -15.842
Net Income Before Extra. Items -15.048 -15.622 -16.696 -17.912 -15.842
Net Income -15.048 -15.622 -16.696 -17.912 -15.842
Income Available to Common Excl. Extra. Items -15.048 -15.622 -16.696 -17.912 -15.842
Income Available to Common Incl. Extra. Items -15.048 -15.622 -16.696 -17.912 -15.842
Diluted Net Income -15.048 -15.622 -16.696 -17.912 -15.842
Diluted Weighted Average Shares 4.68153 4.60491 4.71464 4.80745 4.80732
Diluted EPS Excluding Extraordinary Items -3.21433 -3.39247 -3.54131 -3.72589 -3.29539
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -3.21433 -3.39247 -3.54131 -3.72589 -3.29539
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 79.782 133.309 106.846 133.246 124.338
Cash and Short Term Investments 77.629 128.588 100.444 119.571 122.729
Cash & Equivalents 15.861 16.438 32.507 26.184 11.252
Short Term Investments 61.768 112.15 67.937 93.387 111.477
Prepaid Expenses 1.978 4.41 6.155 13.027 1.221
Total Assets 110.865 174.736 143.84 188.574 140.34
Property/Plant/Equipment, Total - Net 21.679 22.977 26.303 30.284 14.841
Other Long Term Assets, Total 9.404 10.409 10.691 17.542 1.161
Total Current Liabilities 12.122 10.08 8.301 8.863 8.341
Accounts Payable 1.785 1.944 1.995 2.165 2.38
Accrued Expenses 9.442 7.593 6.304 5.946 5.034
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.013 0.012 0.002 0.208 0.266
Other Current Liabilities, Total 0.882 0.531 0.544 0.661
Total Liabilities 28.255 27.47 28.705 31.669 16.242
Total Long Term Debt 0.004 0.018 0 0.002 0.21
Capital Lease Obligations 0.004 0.018 0.002 0.21
Other Liabilities, Total 16.129 17.372 20.404 22.804 7.691
Total Equity 82.61 147.266 115.135 156.905 124.098
Redeemable Preferred Stock 0
Common Stock 0.071 0.07 0.038 0.033 0.025
Retained Earnings (Accumulated Deficit) -357.019 -290.872 -230.311 -171.138 -119.765
Total Liabilities & Shareholders’ Equity 110.865 174.736 143.84 188.574 140.34
Total Common Shares Outstanding 4.44931 4.64682 2.54568 2.15123 1.69352
Additional Paid-In Capital 442.237 438.113 345.394 327.9 243.903
Other Equity, Total -0.161 -0.045 0.014 0.11 -0.065
Other Current Assets, Total 0.175 0.311 0.247 0.648 0.388
Property/Plant/Equipment, Total - Gross 34.819 33.603 34.552 35.915 17.828
Accumulated Depreciation, Total -13.14 -10.626 -8.249 -5.631 -2.987
Long Term Investments 0 8.041 7.502
Treasury Stock - Common -2.518
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 37.78 49.557 62.359 79.782 97.458
Cash and Short Term Investments 33.415 46.261 57.368 77.629 91.656
Cash & Equivalents 24.536 46.261 25.539 15.861 15.622
Short Term Investments 8.879 0 31.829 61.768 76.034
Prepaid Expenses 4.365 3.296 4.991 2.153 4.302
Total Assets 66.254 79.284 93.443 110.865 128.237
Property/Plant/Equipment, Total - Net 18.776 20.06 20.432 21.679 22.141
Property/Plant/Equipment, Total - Gross 33.425 34.259 34.101 34.819 34.668
Accumulated Depreciation, Total -14.649 -14.199 -13.669 -13.14 -12.527
Other Long Term Assets, Total 9.698 9.667 10.652 9.404 8.638
Total Current Liabilities 9.144 9.632 9.737 12.122 11.602
Accounts Payable 0.708 1.082 2.316 1.785 1.718
Accrued Expenses 8.164 7.882 6.715 9.442 8.9
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.008 0.011 0.014 0.013 0.013
Total Liabilities 22.85 24.51 24.731 28.255 27.809
Total Long Term Debt 0 0 0.001 0.004 0.008
Other Liabilities, Total 13.706 14.878 14.993 16.129 16.199
Total Equity 43.404 54.774 68.712 82.61 100.428
Common Stock 0.005 0.073 0.072 0.071 0.07
Additional Paid-In Capital 445.679 444.906 443.829 442.237 441.072
Retained Earnings (Accumulated Deficit) -399.767 -387.689 -372.641 -357.019 -340.323
Other Equity, Total 0.005 0.002 -0.03 -0.161 -0.391
Total Liabilities & Shareholders’ Equity 66.254 79.284 93.443 110.865 128.237
Total Common Shares Outstanding 4.5983 4.57449 4.53635 4.44931 4.68593
Total Receivables, Net 1.5
Accounts Receivable - Trade, Net 1.5
Other Current Liabilities, Total 0.264 0.657 0.692 0.882 0.971
Capital Lease Obligations 0 0 0.001 0.004 0.008
Long Term Investments 0 0
Treasury Stock - Common -2.518 -2.518 -2.518 -2.518
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -66.147 -60.561 -59.173 -51.373 -48.435
Cash From Operating Activities -56.888 -52.198 -39.553 -75.468 -42.47
Cash From Operating Activities 2.52 2.443 2.636 2.702 2.421
Non-Cash Items 6.016 5.72 5.622 4.222 2.924
Cash Interest Paid 0.002 0.002 0.006 0.021 0.043
Changes in Working Capital 0.723 0.2 11.362 -31.019 0.62
Cash From Investing Activities 58.351 -53.253 32.482 10.796 -87.201
Capital Expenditures -0.728 -0.679 -0.395 -1.251 -5.654
Other Investing Cash Flow Items, Total 59.079 -52.574 32.877 12.047 -81.547
Cash From Financing Activities -2.04 89.382 13.394 79.604 82.483
Issuance (Retirement) of Stock, Net -2.027 89.463 13.602 79.87 82.91
Issuance (Retirement) of Debt, Net -0.013 -0.008 -0.208 -0.266 -0.427
Net Change in Cash -0.577 -16.069 6.323 14.932 -47.188
Financing Cash Flow Items 0 -0.073
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -15.622 -66.147 -49.451 -31.539 -15.697
Cash From Operating Activities -21.505 -56.888 -44.495 -29.046 -15.477
Cash From Operating Activities 0.576 2.52 1.907 1.257 0.601
Non-Cash Items 1.189 6.016 4.744 3.334 1.648
Cash Interest Paid 0 0.002 0.002 0.001 0.001
Changes in Working Capital -7.648 0.723 -1.695 -2.098 -2.029
Cash From Investing Activities 30.27 58.351 43.49 43.371 19.758
Capital Expenditures -0.143 -0.728 -0.685 -0.629 -0.477
Other Investing Cash Flow Items, Total 30.413 59.079 44.175 44 20.235
Cash From Financing Activities 0.913 -2.04 0.189 0.138 0.132
Financing Cash Flow Items 0 0 0 0
Issuance (Retirement) of Stock, Net 0.915 -2.027 0.198 0.144 0.135
Issuance (Retirement) of Debt, Net -0.002 -0.013 -0.009 -0.006 -0.003
Net Change in Cash 9.678 -0.577 -0.816 14.463 4.413

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Synlogic Company profile

About Synlogic Inc

Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the drug discovery and development of Synthetic Biotic medicines. Its product pipeline includes Synthetic Biotic medicines for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria. The Company's lead product candidate includes SYNB1618, which is an oral therapy for the treatment of PKU. Its other product candidate SYNB8802 is developed for the treatment of Enteric Hyperoxaluria. The Company developed Synthetic Biotic medicines to treat certain cancers that are designed to modify the tumor microenvironment, activate the immune system and result in tumor reduction. It is developing SYNB1891 for the treatment solid tumors and lymphoma. The Company is conducting Phase II clinical trial with SYNB1618.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Synlogic Inc revenues increased from $545K to $1.8M. Net loss increased 2% to $60.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing increase of 18% to $13.4M (expense), Interest and investment income decrease of 84% to $210K (income).

Industry: Biotechnology & Medical Research (NEC)

301 Binney St Ste 402
CAMBRIDGE
MASSACHUSETTS 02142-1030
US

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

BTC/USD

66,838.15 Price
-1.080% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Oil - Crude

78.30 Price
-0.200% 1D Chg, %
Long position overnight fee 0.0264%
Short position overnight fee -0.0483%
Overnight fee time 22:00 (UTC)
Spread 0.030

XRP/USD

0.65 Price
-0.960% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

US100

18,121.40 Price
-0.490% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading